https://www.reedland.com/wp-content/uploads/2017/04/CV-Therapeutics.jpg292560reedlandhttps://www.reedland.com/wp-content/uploads/2017/05/Reedland-Capital-Partners-Logo.pngreedland2006-04-18 12:17:252017-04-26 12:20:25CV Therapeutics Secures Three Year Equity Financing Commitment
https://www.reedland.com/wp-content/uploads/2017/04/Nektar-Therapeutics.jpg292560reedlandhttps://www.reedland.com/wp-content/uploads/2017/05/Reedland-Capital-Partners-Logo.pngreedland2005-09-08 12:25:232017-04-26 12:29:01Nektar Announces Investor’s Election to Acquire $8M of Nektar’s Common Stock
https://www.reedland.com/wp-content/uploads/2017/04/Nektar-Therapeutics.jpg292560reedlandhttps://www.reedland.com/wp-content/uploads/2017/05/Reedland-Capital-Partners-Logo.pngreedland2005-08-16 12:29:072017-04-26 12:30:44Nektar Therapeutics Announces $24 Million Common Stock Financing
https://www.reedland.com/wp-content/uploads/2017/04/Allied-Capital.jpg292560reedlandhttps://www.reedland.com/wp-content/uploads/2017/05/Reedland-Capital-Partners-Logo.pngreedland2005-07-07 12:30:572017-04-26 12:35:15Allied Capital Invests $77.0 Million in Triax Holdings, LLC
https://www.reedland.com/wp-content/uploads/2017/04/CV-Therapeutics.jpg292560reedlandhttps://www.reedland.com/wp-content/uploads/2017/05/Reedland-Capital-Partners-Logo.pngreedland2004-02-27 12:35:342017-04-26 12:37:34Form 8-K for CV Therapeutics Inc.
